IPCI - IntelliPharmaCeutics International Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.617721
+0.007958 (+1.31%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.609763
Open0.585000
Bid0.580000 x 1100
Ask0.640000 x 1100
Day's Range0.585000 - 0.650000
52 Week Range0.570000 - 10.500000
Volume356,232
Avg. Volume202,081
Market Cap4.454M
Beta (3Y Monthly)-0.74
PE Ratio (TTM)N/A
EPS (TTM)-0.316000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.50
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Intellipharmaceutics Announces Closing of US $14.3 Million Underwritten Public Offering

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the closing of its previously announced underwritten public offering in the United States, resulting in the sale of 2,775,231 common shares, pre-funded warrants exercisable for 16,563,335 common shares, at an exercise price of US$0.01 per share (the "Pre-Funded Warrants"), and warrants exercisable for 20,000,000 common shares, at an exercise price of US$0.75 per share (the "Firm Warrants").

  • ACCESSWIRE5 days ago

    Intellipharmaceutics Announces Third Quarter 2018 Results

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2018. "We made great progress with respect to our development programs in the third quarter, despite challenging financial circumstances," said Dr. Isa Odidi, CEO of Intellipharmaceutics. In October 2018, we entered into an Underwriting Agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), pursuant to which we agreed to issue and sell, in an underwritten public offering (the "October 2018 Offering"), 827,970 common shares and an aggregate of 16,563,335 pre-funded warrants ("Pre-Funded Warrants") exercisable into an aggregate of 16,563,335 common shares (the "Warrant Shares") together with common share purchase warrants to purchase up to an aggregate of 17,391,305 common shares ("Firm Warrants").

  • Benzinga8 days ago

    Don't Fixate On Market Woes, Just Make Your Trades

    Beyond my recent losses, October has actually been a strong month for me, although some in the chat are wondering how the recent market-wide selloff is affecting day traders. It was a fairly typical day for me, I was up, then down, then up again. Two of the top stocks to appear on my premarket scanner on Thursday, Spherix Inc. (NASDAQ: SPEX) and Compugen Ltd. (NASDAQ: CGEN), both collapsed on the opening bell.

  • FSCWire8 days ago

    Intellipharmaceutics Announces Pricing of $13 Million Upsized Underwritten Public Offering

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of an aggregate of 17,391,305 units. Each unit is comprised of one common share (or common share equivalent) and one warrant to purchase one common share. The units are being offered at a public offering price of $0.75 per unit.

  • ACCESSWIRE8 days ago

    Intellipharmaceutics Announces Pricing of $13 Million Upsized Underwritten Public Offering

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of an aggregate of 17,391,305 units. Each unit is comprised of one common share (or common share equivalent) and one warrant to purchase one common share. The units are being offered at a public offering price of $0.75 per unit.

  • FSCWire9 days ago

    Intellipharmaceutics Announces Completion of the Clinical Component of Category 2 and 3 Human Abuse Liability Studies for Oxycodone ER

    TSX : IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has completed the clinical part of its Category 2 and 3 human abuse liability studies for its Oxycodone ER (oxycodone hydrochloride extended-release formulation) product candidate to support its abuse-deterrent label claims for both the oral and intranasal route of administration. The Company's new drug application ("NDA") for an abuse-deterrent version of Oxycodone ER was accepted for filing by the U.S. Food and Drug Administration ("FDA") in February 2017.

  • ACCESSWIRE9 days ago

    Intellipharmaceutics Announces Completion of the Clinical Component of Category 2 and 3 Human Abuse Liability Studies for Oxycodone ER

    TORONTO, ON / ACCESSWIRE / October 10, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX : IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE19 days ago

    Intellipharmaceutics Regains Compliance with NASDAQ Minimum Bid Price Requirement; Also Receives Requested Extension from NASDAQ Panel

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listing Qualifications notifying the Company that it had regained compliance with Nasdaq's minimum bid price requirement. The letter noted that as of September 28, 2018, the Company evidenced a closing bid price of its common shares in excess of the $1.00 minimum requirement for at least ten consecutive business days.

  • ACCESSWIRElast month

    Intellipharmaceutics Announces One-for-10 Reverse Stock Split

    TORONTO, ONTARIO / ACCESSWIRE / September 13, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid-dosage drugs, announced today that it implemented a one-for-ten share consolidation (the "reverse split"). At a special meeting of the Company's shareholders held on August 15, 2018, the Company's shareholders granted the Company's Board of Directors discretionary authority to implement a consolidation of the issued and outstanding common shares of the Company on the basis of a consolidation ratio within a range from five (5) pre-consolidation common shares for one (1) post-consolidation common share to fifteen (15) pre-consolidation common shares for one (1) post-consolidation common share.

  • ACCESSWIRElast month

    Intellipharmaceutics Closes US$0.5 Million Convertible Debenture Financing

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it issued in a private placement financing (the ''Financing'') an unsecured convertible debenture in the principal amount of US$0.5 million (the ''Debenture''), which will mature September 1, 2020. The Debenture bears interest at a rate of 10% per annum, payable monthly, is pre-payable at any time at the option of the Company, and is convertible at any time into common shares at a conversion price of US$0.30 per common share at the option of the holder. If the Debenture is fully converted into common shares of the Company, the shares would represent approximately 3.8% of the Company's currently issued common shares on a non-diluted basis.

  • ACCESSWIRE3 months ago

    Blog Exposure - Cambrex Announces Halo Pharma Acquisition

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want access to our free research report on Cambrex Corp. (NYSE: CBM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBM as the Company's latest news hit the wire. On July 23, 2018, the Company announced that it has inked a deal to acquire Halo Pharma, which is a leading dosage form Contract Development and Manufacturing Organization (CDMO), majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million in cash. Active-Investors.com is currently working on the research report for IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), which also belongs to the Healthcare sector as the Company Cambrex.

  • Associated Press3 months ago

    Intellipharmaceutics: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Toronto-based company said it had a loss of 7 cents. The extended-release drug developer posted revenue of $577,000 in the period. The company's shares closed at 47 cents. A year ...

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces Second Quarter 2018 Results

    TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listings Qualification staff (the "Staff") formally notifying the Company that its 180-day grace period for the $1.00 per share bid price requirement period has expiredand that therefore the Company is non-compliant with Nasdaq Listing Rule 5550(a)(2). While the Company understands has the opportunity to provide a submission to the Nasdaq Hearings Panel (the''Panel''), it does not intend to do so since the Company proactively addressed the bid price issue at the hearing held on May 17, 2018, and since Panel has already granted the Company a further extension within which to address the bid price issue.

  • ACCESSWIRE5 months ago

    Nasdaq Hearings Panel Grants Intellipharmaceutics' Request for Continued Listing

    TORONTO, ON / ACCESSWIRE / May 22, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received notice from the Nasdaq Hearings Panel granting its request for continued listing until September 28, 2018 while the Company works to regain compliance with Nasdaq's requirements. At a hearing held on May 17, 2018, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements.

  • ACCESSWIRE5 months ago

    Intellipharmaceutics Reports Director Election Results

    TORONTO, ON / ACCESSWIRE / May 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, ...

  • ACCESSWIRE5 months ago

    Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has commenced its Category 2 and 3 human abuse liability studies for the Company's Oxycodone ER product candidate to support its abuse-deterrent label claims for the intranasal route of administration. "This is a very important step towards resubmission of our NDA for Oxycodone ER," commented Dr. Isa Odidi, CEO of Intellipharmaceutics.

  • ACCESSWIRE6 months ago

    Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination

    TORONTO, ON / ACCESSWIRE / April 27, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the ...

  • ACCESSWIRE6 months ago

    Wired News – Asterias Biotherapeutics: Clinical Grade Lot Released to Support Dosing of Subjects in First Clinical Study of AST-VAC2 in Non-Small Cell Lung Cancer

    LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Asterias Biotherapeutics, Inc. (NYSE: AST) ("Asterias"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AST as the Company's latest news hit the wire. On April 25, 2018, the California-based biotechnology Company announced that Cancer Research UK has released the first cGMP (current Good Manufacturing Practice) clinical grade lot of AST-VAC2 to be used to dose subjects enrolling into the first clinical study evaluating AST-VAC2 in non-small cell lung cancer (NSCLC).

  • ACCESSWIRE6 months ago

    Intellipharmaceutics Receives Delisting Determination from NASDAQ Staff; Company to Request Hearing

    TORONTO, ON / ACCESSWIRE / April 23, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff has determined to delist the Company's securities from Nasdaq. On September 20, 2017, Staff notified the Company that it did not comply with the minimum $2.5 million stockholders' equity, $35 million market value of listed securities, or $500,000 of net income from continuing operations requirements set forth in Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), respectively.

  • ACCESSWIRE6 months ago

    Intellipharmaceutics Announces First Quarter 2018 Results

    TORONTO, ON / ACCESSWIRE / April 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE7 months ago

    Intellipharmaceutics Announces Closing of US$1.8 Million Financing

    TORONTO, ON / ACCESSWIRE / March 21, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE7 months ago

    Intellipharmaceutics Announces US$1.8 Million Registered Direct Offering

    TORONTO, ON / ACCESSWIRE / March 19, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE7 months ago

    Intellipharmaceutics Announces Closing of US$3.5 Million Financing

    TORONTO, ON / ACCESSWIRE / March 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE7 months ago

    Intellipharmaceutics Announces US$3.5 Million Registered Direct Offering

    TORONTO, ON / ACCESSWIRE / March 14, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...